Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.

The role of tumor-infiltrating B cells (TIL-Bs) in shaping anti-tumor responses in the context of immune checkpoint blockade remains incompletely understood. Here, we interrogate the humoral response in resected lung tumors from patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant PD-1 blockade. We find that tumors orchestrate tertiary lymphoid structures with CD138+ plasma cells, from which we clone recombinant monoclonal antibodies (mAbs) using B cell receptors (BCRs) exhibiting somatic hypermutation and class switching. Several mAbs bind cell-surface citrullinated proteins, characteristic of cancer cells. Chimeric antigen receptor (CAR) T redirected with the soluble chain fragment variable (scFv) of our lead candidate antibody (PC-1) specifically target tumor cells and tumor-promoting myeloid cells in vivo without off-target activity. Moreover, ablation of the citrullination enzyme PADI2 in tumor-bearing mice eliminates reactivity to PC-1 and cytotoxic killing by the CAR. Our results implicate a therapeutic potential for tumor-infiltrating plasma cells that may be harnessed for cancer treatment.

Duke Scholars

Author Wilton Bryan Williams Surgery, Surgical Sciences

Author Scott Joseph Antonia Medicine, Medical Oncology

Author Kent James Weinhold Surgery, Surgical Sciences

Author Priyamvada Acharya Surgery, Surgical Sciences

Author John Wirthlin Hickey Biomedical Engineering

Author Eziafa I Oduah Medicine, Medical Oncology

Author Neal Edward Ready Medicine, Medical Oncology

Author Simon Gray Gregory Neurosurgery, Neuro-Oncology